Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nettardep is a multi-ingredient dietary supplement (nutraceutical) developed by Logus Pharma, primarily indicated for the management of cough and the promotion of respiratory tract health. The formulation consists of standardized plant extracts, including Ivy (*Hedera helix*), Marshmallow (*Althaea officinalis*), and Thyme (*Thymus vulgaris*). Ivy extract acts as a secretolytic and spasmolytic agent, facilitating the clearance of mucus by increasing the fluidity of bronchial secretions. Marshmallow provides a demulcent effect, coating the oropharyngeal mucosa to soothe irritation and protect against external agents. Thyme contributes antiseptic and antitussive properties, supporting the functionality of the upper respiratory tract. As a consumer health product, Nettardep is marketed for symptomatic relief and is not classified as an investigational pharmaceutical drug in clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nettardep.